Allergy Therapeutics (LON:AGY) had its price target decreased by stock analysts at FinnCap from GBX 47 ($0.61) to GBX 40 ($0.52) in a research note issued on Friday. The firm presently has a “corporate” rating on the stock. FinnCap’s price target would indicate a potential upside of 387.80% from the stock’s current price.
Separately, Numis Securities restated a “buy” rating and set a GBX 35 ($0.46) price objective on shares of Allergy Therapeutics in a research report on Monday, March 18th.
Shares of LON AGY opened at GBX 8.20 ($0.11) on Friday. Allergy Therapeutics has a one year low of GBX 8 ($0.10) and a one year high of GBX 29 ($0.38). The stock has a market cap of $52.17 million and a price-to-earnings ratio of -16.40. The company has a debt-to-equity ratio of 6.20, a current ratio of 3.74 and a quick ratio of 3.08.
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
See Also: Retained Earnings
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.